| scholarly article | Q13442814 |
| P2093 | author name string | F Maggi | |
| M Bendinelli | |||
| M Pistello | |||
| D Del Mauro | |||
| D Matteucci | |||
| S Giannecchini | |||
| P2860 | cites work | Development of IL-2 Independent Feline Lymphoid Cell Lines Chronically Infected with Feline Immunodeficiency Virus: Importance for Diagnostic Reagents and Vaccines | Q41709030 |
| Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera | Q41722321 | ||
| The feline lymphoid cell line MBM and its use for feline immunodeficiency virus isolation and quantitation | Q42804216 | ||
| Differences in hepatitis C virus quasispecies composition between liver, peripheral blood mononuclear cells and plasma | Q42983902 | ||
| Analysis of the genetic diversity and phylogenetic relationship of Italian isolates of feline immunodeficiency virus indicates a high prevalence and heterogeneity of subtype B. | Q45760601 | ||
| Most potential linear B cell epitopes of Env glycoproteins of feline immunodeficiency virus are immunogenically silent in infected cats | Q45760749 | ||
| Quasispecies and naturally occurring superinfection in feline immunodeficiency virus infection | Q45766765 | ||
| Evaluation of subunit vaccines against feline immunodeficiency virus infection | Q45769173 | ||
| Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev | Q45771982 | ||
| Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors | Q45772545 | ||
| Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus | Q45779729 | ||
| Virus neutralization reveals antigenic variation among feline immunodeficiency virus isolates | Q45781771 | ||
| Serological diagnosis of feline immunodeficiency virus infection based on synthetic peptides from Env glycoproteins | Q45786785 | ||
| Comparison of serological tests for the diagnosis of feline immunodeficiency virus infection of cats | Q45788671 | ||
| Monoclonal antibodies to immunodominant and neutralizing domains of the envelope surface protein of feline immunodeficiency virus | Q45789946 | ||
| Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus | Q45859822 | ||
| Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads | Q71011098 | ||
| Neutralization of HIV-1 | Q72160001 | ||
| Neutralization of animal viruses | Q72886254 | ||
| Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection | Q28286243 | ||
| Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection | Q28304764 | ||
| Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen. | Q35365474 | ||
| Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines | Q35839932 | ||
| Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry. | Q35839973 | ||
| Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. | Q35841780 | ||
| Human plasma enhances the infectivity of primary human immunodeficiency virus type 1 isolates in peripheral blood mononuclear cells and monocyte-derived macrophages | Q35847492 | ||
| Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. | Q35849408 | ||
| Protective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus. | Q35851163 | ||
| Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. | Q35853750 | ||
| Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent i | Q35853761 | ||
| Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies | Q35854001 | ||
| The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate | Q35869892 | ||
| Feline immunodeficiency virus vaccination: characterization of the immune correlates of protection | Q35871792 | ||
| Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization | Q35872254 | ||
| Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells | Q35879840 | ||
| Genetic diversity of feline immunodeficiency virus: dual infection, recombination, and distinct evolutionary rates among envelope sequence clades | Q35886001 | ||
| Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted. | Q35898304 | ||
| Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1 | Q36625449 | ||
| Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals | Q36803017 | ||
| Neutralizing antibodies in cats infected with feline immunodeficiency virus | Q37128778 | ||
| Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion | Q39535471 | ||
| Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines | Q39868882 | ||
| Neutralization of feline immunodeficiency virus by polyclonal feline antibody: simultaneous involvement of hypervariable regions 4 and 5 of the surface glycoprotein | Q39871315 | ||
| Incubation time for feline immunodeficiency virus cultures | Q40011380 | ||
| Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system. | Q40038277 | ||
| Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus. | Q40043741 | ||
| Identification of a linear neutralization site within the third variable region of the feline immunodeficiency virus envelope | Q40046473 | ||
| Feline immunodeficiency virus as a model for development of molecular approaches to intervention strategies against lentivirus infections | Q40551633 | ||
| Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype | Q41048122 | ||
| Structure and variations of feline immunodeficiency virus envelope glycoproteins | Q41090569 | ||
| HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. | Q41120023 | ||
| Neutralization of primary human immunodeficiency virus type 1 isolates: a study of parameters implicated in neutralization in vitro | Q41143013 | ||
| Neutralization sensitivity and accessibility of continuous B cell epitopes of the feline immunodeficiency virus envelope. | Q41210835 | ||
| Reduced sensitivity to strain-specific neutralization of laboratory-adapted feline immunodeficiency virus after one passage in vivo: association with amino acid substitutions in the V4 region of the surface glycoprotein | Q41237653 | ||
| Antibody neutralization of HIV-1. | Q41305709 | ||
| FIV infection of the domestic cat: an animal model for AIDS. | Q41459259 | ||
| HIV type 1 coreceptors, neutralization serotypes, and vaccine development | Q41488142 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | feline immunodeficiency virus | Q1129598 |
| P304 | page(s) | 2199-2207 | |
| P577 | publication date | 1998-03-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Autologous and heterologous neutralization analyses of primary feline immunodeficiency virus isolates | |
| P478 | volume | 72 |
| Q39548535 | AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: detailed analysis of the humoral immune response to a protective vaccine |
| Q36473694 | AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: protection from an intraclade challenge administered systemically or mucosally by an attenuated vaccine |
| Q39602555 | AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: reevaluation of neutralizing antibody levels elicited by a protective and a nonprotective vaccine after removal of antisubstrate cell antibodies |
| Q44858504 | AIDS vaccination studies using feline immunodeficiency virus as a model: immunisation with inactivated whole virus suppresses viraemia levels following intravaginal challenge with infected cells but not following intravenous challenge with cell-free |
| Q35024266 | AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogens |
| Q39732473 | Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein |
| Q33840406 | During readaptation in vivo, a tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistance at different times in individual hosts but through changes at the same position of the surface glycoprotein |
| Q37015529 | Feline immunodeficiency virus neuropathogenesis: from cats to calcium |
| Q33854938 | Feline immunodeficiency virus-infected cat sera associated with the development of broad neutralization resistance in vivo drive similar reversions in vitro |
| Q36462709 | Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency virus replication in vitro and provide a rationale to redesign antiretroviral treatment for feline AIDS |
| Q33641801 | Kinetics of replication of a partially attenuated virus and of the challenge virus during a three-year intersubtype feline immunodeficiency virus superinfection experiment in cats |
| Q36099050 | Role of Env in resistance of feline immunodeficiency virus (FIV)-infected cats to superinfection by a second FIV strain as determined by using a chimeric virus |
Search more.